Processa Pharmaceuticals (PCSA) Price & Analysis

Q: What was Processa Pharmaceuticals’s price range in the past 12 months?

Processa Pharmaceuticals lowest stock price was $0.15 and its highest was $1.50 in the past 12 months.

Q: What is Processa Pharmaceuticals’s market cap?

Processa Pharmaceuticals’s market cap is $17.42M.

Q: When is Processa Pharmaceuticals’s upcoming earnings report date?

Processa Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 241 days.

Q: How were Processa Pharmaceuticals’s earnings last quarter?

Processa Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported -$0.075 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.005.

Q: Is Processa Pharmaceuticals overvalued?

According to Wall Street analysts Processa Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Processa Pharmaceuticals pay dividends?

Processa Pharmaceuticals does not currently pay dividends.

Q: What is Processa Pharmaceuticals’s EPS estimate?

Processa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Processa Pharmaceuticals have?

Processa Pharmaceuticals has 50,349,148 shares outstanding.

Q: What happened to Processa Pharmaceuticals’s price movement after its last earnings report?

Processa Pharmaceuticals reported an EPS of -$0.075 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -2.857%.

Q: Which hedge fund is a major shareholder of Processa Pharmaceuticals?

Currently, no hedge funds are holding shares in PCSA

Compare

320 Followers

PCSA Stock Chart & Stats

$0.28

-$0.13(-13.68%)

At close: Jan 08 4:00 PM EST

$0.28

-$0.13(-13.68%)

Day’s Range― - ―

52-Week Range$0.15 - $1.50

Previous CloseN/A

Volume113.34K

Average Volume (3M)17.04M

Market Cap

$17.42M

Enterprise Value-$3.72M

Total Cash (Recent Filing)$6.31M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.30

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding50,349,148

10 Day Avg. Volume46,022,589

30 Day Avg. Volume17,044,111

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)1.59

Price to Sales (P/S)0.00

P/FCF Ratio-0.24

Enterprise Value/Market Cap-0.21

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.29

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentPositive interim data from the NGC-Cap mid-stage trial should constitute a meaningful value inflection point.

Financial StabilityThe company ended 2Q25 with roughly $6.9M in cash and cash equivalents, which is expected to be sufficient to fund operations into early 2026.

Strategic InvestmentsProcessa recently announced that it secured a strategic investment and is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.

Bears Say

Financial ConstraintsAdditional capital will be required to fully fund the ongoing Phase 2 trial, and there is a concern that challenging financing conditions can limit the ability to complete the study.

Market ComplianceProcessa has received a notice from the NASDAQ exchange indicating that it is not currently in compliance with the minimum bid price requirement due to the low current share price.

Patient Enrollment DelaysThe required patients for the interim analysis of the Phase 2 trial have not enrolled yet, and it remains unclear when they will enroll due to the cash balance.

Processa Pharmaceuticals News

Processa Pharmaceuticals Reports Q3 2025 Financial Results

Processa Pharmaceuticals, Inc. ( ($PCSA) ) has released its Q3 earnings. Here is a breakdown of the information...

26d ago

PCSA

Processa Pharmaceuticals Advances Breast Cancer Treatment with Phase 2 Study

Processa Pharmaceuticals, Inc. (($PCSA)) announced an update on their ongoing clinical study. Processa Pharmaceuticals, Inc. is conducting a...

1M ago

PCSA

Processa Pharmaceuticals Approves Key Shareholder Proposals

Processa Pharmaceuticals ( ($PCSA) ) has issued an update. Processa Pharmaceuticals held a Special Meeting of Shareholders on...

3M ago

PCSA

Processa Pharmaceuticals Reschedules Special Shareholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has issued an announcement. On September 2, 2025, Processa Pharmaceuticals held a Special...

3M ago

PCSA

Processa Pharmaceuticals Adjourns Special Shareholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has shared an announcement. On September 2, 2025, Processa Pharmaceuticals, Inc. held a...

3M ago

PCSA

Processa Pharmaceuticals price target lowered to $1 from $2 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $1 from $2...

3M ago

PCSA

Processa Pharmaceuticals Relocates 2025 Stockholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has issued an announcement. On August 25, 2025, Processa Pharmaceuticals, Inc. announced a...

4M ago

PCSA

Processa Pharmaceuticals Reports Increased Losses Amid Strategic Developments

Processa Pharmaceuticals, Inc. ( ($PCSA) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

PCSA

Processa Pharmaceuticals Raises $1.3M in Private Placement

The latest update is out from Processa Pharmaceuticals ( ($PCSA) ). On August 4, 2025, Processa Pharmaceuticals entered...

4M ago

PCSA

Processa secures strategic investment, evaluates crypto strategy

Processa Pharmaceuticals (PCSA) announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency...

4M ago

PCSA

Processa Pharmaceuticals Files Prospectus for Stock Sale

Processa Pharmaceuticals ( ($PCSA) ) has provided an announcement. On July 25, 2025, Processa Pharmaceuticals filed a prospectus...

5M ago

PCSA

Processa Pharmaceuticals Approves Key Proposals at Annual Meeting

The latest update is out from Processa Pharmaceuticals ( ($PCSA) ). On July 18, 2025, Processa Pharmaceuticals held...

5M ago

PCSA

Processa terminates license agreement for PCS3117

Processa Pharmaceuticals (PCSA) provides updates on its product pipeline, upcoming milestones and business activities. Key Portfolio Updates: PCS6422:...

5M ago

PCSA

Processa Pharmaceuticals price target lowered to $2 from $6 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $2 from $6 and keeps a...

5M ago

PCSA

PCSA FAQ

What was Processa Pharmaceuticals’s price range in the past 12 months?

Processa Pharmaceuticals lowest stock price was $0.15 and its highest was $1.50 in the past 12 months.

What is Processa Pharmaceuticals’s market cap?

Processa Pharmaceuticals’s market cap is $17.42M.

When is Processa Pharmaceuticals’s upcoming earnings report date?

Processa Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 241 days.

How were Processa Pharmaceuticals’s earnings last quarter?

Processa Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported -$0.075 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.005.

Is Processa Pharmaceuticals overvalued?

According to Wall Street analysts Processa Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Processa Pharmaceuticals pay dividends?

Processa Pharmaceuticals does not currently pay dividends.

What is Processa Pharmaceuticals’s EPS estimate?

Processa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Processa Pharmaceuticals have?

Processa Pharmaceuticals has 50,349,148 shares outstanding.

What happened to Processa Pharmaceuticals’s price movement after its last earnings report?

Processa Pharmaceuticals reported an EPS of -$0.075 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -2.857%.

Which hedge fund is a major shareholder of Processa Pharmaceuticals?

Currently, no hedge funds are holding shares in PCSA

Company Description

Processa Pharmaceuticals

Processa Pharmaceuticals (PCSA) is a clinical-stage biopharmaceutical company focused on developing innovative drug products to address unmet medical needs. Operating primarily in the biopharmaceutical and healthcare sectors, the company is committed to advancing its pipeline of promising drug candidates through various stages of clinical development to ultimately improve patient outcomes.

Processa Pharmaceuticals (PCSA) Earnings & Revenues

Historic Earnings Reports

PCSA Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.39,0.36,0.33,0.3,0.27,0.24,0.21,0.18,0.15,0.12,0.08999999999999997,0.06,0.02999999999999997,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.39,0.36,0.33,0.3,0.27,0.24,0.21,0.18,0.15,0.12,0.08999999999999997,0.06,0.02999999999999997,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.39,0.36,0.33,0.3,0.27,0.24,0.21,0.18,0.15,0.12,0.08999999999999997,0.06,0.02999999999999997,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.25,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.3,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >